Rituximab Plus Interleukin-2 in Treating Patients With Lymphoma
Completed · Phase 1/Phase 2
Conditions studied: Lymphoma
In brief
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining rituximab and interleukin-2 intreating patients who have low-grade mantle cell lymphoma or follicular lymphoma.
Key facts
- Study ID
- NCT00003356
- Run by
- University of Rochester
- People needed
- 58
- Starts
- 1997-11-01
- Expected to finish
- 2002-05-01
- Last updated by the study team
- 2013-10-16
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Rochester Cancer Center — Rochester, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.